Weight Regain After Stopping GLP-1 Medications: How Much and How Fast? | Research

The takeaway

A large retrospective study found that patients who stopped GLP-1 medications regained weight, but the rate and extent depended on how long they had been on the drugs.

Weight regain after discontinuation
Pattern and extent influenced by duration of prior GLP-1 use

What the researchers found

Patients experienced weight regain after discontinuing GLP-1 medications, with patterns influenced by the duration of prior treatment.

Why it matters

Understanding weight regain patterns after stopping GLP-1 drugs is critical for setting patient expectations and planning long-term treatment strategies.

How the study worked

Retrospective cohort study using TriNetX electronic health records (2014-2023) with linear mixed effects models and propensity score adjustment.

What this study cannot tell us

Retrospective design using EHR data; reasons for discontinuation unknown; BMI measurements may be irregular in real-world records.

How to read the evidence

Retrospective cohort study — provides real-world evidence but cannot establish causation. Subject to confounding despite statistical adjustments.

When this study was published

Published 2026 in Obesity. Uses data through November 2023.

The bigger picture

Weight regain after stopping GLP-1 medications is a central concern in obesity medicine. This data supports the emerging view that obesity may require ongoing pharmacotherapy, similar to other chronic conditions.

Questions still open

Is there a minimum treatment duration that protects against rapid weight regain?
Can lifestyle interventions during GLP-1 use reduce the magnitude of post-discontinuation regain?

Common questions

Do you gain all the weight back after stopping GLP-1 drugs?

This study found weight regain does occur after stopping GLP-1 medications, but the amount and speed depend on how long the patient was on the medication.

Does this mean you have to take GLP-1 drugs forever?

The findings support treating obesity as a chronic condition that may require ongoing pharmacotherapy, though individual strategies should be discussed with a healthcare provider.

Read the original research

Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.

Obesity (Silver Spring, Md.), 34(2), 482-490

View on PubMed ↗Publisher’s paper ↗

Citation

Alexander, G Caleb; Xu, Yizhen; Xiao, Xuya; Lewis, Sydney V; Zeger, Scott; Mehta, Hemalkumar B. (2026). Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.. Obesity (Silver Spring, Md.), 34(2), 482-490. https://doi.org/10.1002/oby.70076